Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation

ISSN： 1174-5886

Source： Drugs in R&D, Vol.11, Iss.1, 2011-03, pp. : 1-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Safety Profile of Sildenafil in Singaporean Men with Erectile Dysfunction: Pre-marketing Experience (ASSESS-I Evaluation)

By Lim PHC Ng FC Cheng CWS Wong MYC Chee CTY Moorthy P Vasan SS

The Journal of International Medical Research, Vol. 30, Iss. 2, 2002-03 ,pp. : 137-143

Field House Publishing

Access to resources Recommend Favorite

An Evaluation of the Cardiovascular Safety Profile of Duloxetine: Findings from 42 Placebo-Controlled Studies

By Wernicke Joachim

Drug Safety, Vol. 30, Iss. 5, 2007-01 ,pp. : 437-455

Adis International

Access to resources Recommend Favorite

The Practice of Pre-Marketing Safety Assessment in Drug Development

By Chuang-Stein Christy Xia H. Amy

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 1, 2013-01 ,pp. : 3-25

Taylor & Francis Ltd

Access to resources Recommend Favorite

Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine

By Gras J. Cardelus I. Llenas J. Palacios J.M.

European Journal of Pharmacology, Vol. 410, Iss. 1, 2000-12 ,pp. : 53-59

Elsevier

Access to resources Recommend Favorite

The Cardiovascular Safety Profile of Renzapride, a Novel Treatment for Irritable Bowel Syndrome

By Meyers NL Hickling RI

The Journal of International Medical Research, Vol. 35, Iss. 6, 2007-11 ,pp. : 848-866

Field House Publishing

Access to resources Recommend Favorite